Structure Therapeutics Inc. (GPCR) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$20.85

From 52W high−78.21%

Volume291088.00

Market cap$1.46B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$20.85

From 52W high

−78.21%

Volume

291088.00

Market cap

$1.46B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

22.5

MomentumView details →

1D Return

+0.41%

YTD Return

−70.82%

SummaryUpdated Jun 1, 2026

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in South San Francisco, California. The company was formerly known as ShouTi Inc. before rebranding and went public in February 2023. Structure Therapeutics focuses on developing novel oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) to treat chronic diseases with significant unmet medical needs, particularly in diabetes, obesity, and pulmonary diseases.

Ask drillr about Structure Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−15.88%

ROA (TTM)

−15.09%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+2.88%

FCF YoY

−36.70%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−2.56%

EBITDA YoY

−6.20%

MomentumView details →

1D Return

+0.41%

YTD Return

−70.82%

1Y Return

−36.98%

RSI (14)

22.5

vs 50D SMA

−35.97%

vs 200D SMA

−57.75%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

20.75x

Quick Ratio

20.75x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.49

EPS Surprise

−25.64%

Beats (12Q)

6/12

Next Q EPS Est

−$0.51

Avg Surprise (4Q)

−7.67%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−215.06M

Op. CF (TTM)

−220.25M

Next earningsNov 5, 2026 →

Latest newsMore news →

Structure Therapeutics announced an upcoming poster presentation on aleniglipron at The Obesity Society's ObesityWeek 2026 meeting.16d ago

Structure Therapeutics reported positive clinical data for its oral small molecule amylin receptor agonist ACCG-2671 and GLP-1 receptor agonist aleniglipron for chronic weight management, including Phase 1/2a results for ACCG-2671 and Phase 2 OLE results for aleniglipron showing up to 16.2% mean body weight reduction at 72 weeks.57d ago

Similar companies

Tyra Biosciences, Inc.TYRA Rapport Therapeutics, Inc. Common StockRAPP Mineralys Therapeutics, Inc.MLYS UroGen Pharma Ltd.URGN KalVista Pharmaceuticals, Inc.KALV Eton Pharmaceuticals, Inc.ETON Find similar companies →

Latest newsMore news →

Structure Therapeutics announced an upcoming poster presentation on aleniglipron at The Obesity Society's ObesityWeek 2026 meeting.16d ago Structure Therapeutics reported positive clinical data for its oral small molecule amylin receptor agonist ACCG-2671 and GLP-1 receptor agonist aleniglipron for chronic weight management, including Phase 1/2a results for ACCG-2671 and Phase 2 OLE results for aleniglipron showing up to 16.2% mean body weight reduction at 72 weeks.57d ago Structure Therapeutics is advancing its oral GLP-1 candidate aleniglipron into Phase 3 studies, with pivotal data expected in Q4 2028.75d ago